Roche (OTCMKTS:RHHBY) Upgraded at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of Roche (OTCMKTS:RHHBY) from an underweight rating to a neutral rating in a research report report published on Monday, Marketbeat.com reports.

Other equities research analysts have also recently issued research reports about the company. Hsbc Global Res raised Roche from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 2nd. Jefferies Financial Group cut Roche from a “hold” rating to a “moderate sell” rating in a report on Monday, October 27th. HSBC raised Roche from a “hold” rating to a “buy” rating and set a $50.00 price target on the stock in a research report on Thursday, October 2nd. Morgan Stanley restated an “underweight” rating on shares of Roche in a research note on Tuesday, December 2nd. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Roche from a “sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Three investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.00.

Roche Stock Performance

Roche stock opened at $50.43 on Monday. The company has a 50-day simple moving average of $45.24 and a 200-day simple moving average of $42.17. Roche has a one year low of $34.10 and a one year high of $50.67.

Institutional Investors Weigh In On Roche

A number of hedge funds have recently made changes to their positions in the company. Hancock Whitney Corp raised its position in Roche by 4.8% in the 3rd quarter. Hancock Whitney Corp now owns 24,488 shares of the company’s stock valued at $1,024,000 after purchasing an additional 1,116 shares during the last quarter. Verity Asset Management Inc. increased its holdings in Roche by 20.9% during the 3rd quarter. Verity Asset Management Inc. now owns 10,990 shares of the company’s stock worth $459,000 after purchasing an additional 1,898 shares in the last quarter. Douglass Winthrop Advisors LLC bought a new position in shares of Roche during the 3rd quarter worth approximately $201,000. Curio Wealth LLC acquired a new position in shares of Roche during the 3rd quarter worth about $25,000. Finally, Vestmark Advisory Solutions Inc. acquired a new stake in shares of Roche in the third quarter valued at about $597,000.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.